The record first. Published May 19, 2022, US20220151553A1 (CPC A61B 5/14532 and 5/0205). The named inventor is Phillip Bosua. This is a published application, not a grant. It describes a wrist-worn non-invasive analyte sensor — the long-pursued capability of reading glucose through the skin without a needle or implanted sensor.
Zoom out to the addressable market. Non-invasive glucose is the feature that would move a wearable from a fitness accessory to a tool for the hundreds of millions managing or monitoring metabolic health. That is not a margin tweak; it is a redefinition of who the device is for. A patent staking that capability is a long bet on the largest possible expansion of the wearable's market.
The business framing is the regulatory moat. Any analyte-sensing claim that approaches medical use invites a long, expensive validation and clearance path. That barrier cuts both ways: it delays revenue, but it also means whoever clears it first owns a moat competitors cannot quickly cross. The patent is the option; clearance is the gate.
Comparability discipline applies. "Health sensing" spans heart rate (mature), oximetry (established), and glucose (unproven non-invasively). The publication pins this claim to the hardest, highest-payoff modality — useful for separating incremental sensing from category-redefining bets, and a reminder that a publication is intent, not a cleared product.
What the document does not disclose is accuracy, clearance, or economics. It will not tell you whether the sensing works to clinical standard or when it could ship. It establishes a fenced position on the holy-grail feature; everything material is undisclosed.
For investors, the throughline is this: the wearable's biggest possible market expansion hinges on non-invasive glucose, and the patent record is where you see who is betting on clearing that moat first.